A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

PHASE2RecruitingINTERVENTIONAL
Enrollment

436

Participants

Timeline

Start Date

May 21, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Severe Asthma
Interventions
DRUG

Verekitug

Verekitug subcutaneous injection.

DRUG

Placebo

Verekitug matching placebo.

Trial Locations (15)

21162

RECRUITING

Chesapeake Clinical Research Inc, White Marsh

32789

RECRUITING

Clinical Site Partners dba Flourish research, Winter Park

33165

RECRUITING

Phoenix Medical Research, Miami

33176

RECRUITING

Health and Life Research Institute, LLC, Miami

33317

RECRUITING

Edward Jenner Research Group, LLC, Plantation

43617

RECRUITING

Toledo Institute of Clinical Research Inc, Toledo

48336

RECRUITING

Pulmonary Research Institute of Southeast Michigan (PRISM), Farmington Hills

73034

RECRUITING

OK Clinical Research, LLC, Edmond

75069

RECRUITING

Metroplex Pulmonary and Sleep Center Drive, McKinney

75209

RECRUITING

Alina Clinical Trials, LLC, Dallas

77375

RECRUITING

DM Clinical Tomball, Tomball

79902

RECRUITING

El Paso Pulmonary Association, El Paso

83706

RECRUITING

Treasure Valley Medical Research, Boise

91324

RECRUITING

California Medical Research Associates Inc., Northridge

92683

RECRUITING

Allianz Research Institute, Westminster

All Listed Sponsors
lead

Upstream Bio Inc.

INDUSTRY